Actively Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Led by CRISPR Therapeutics AG · Updated on 2026-03-24
90
Participants Needed
18
Research Sites
205 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
CONDITIONS
Official Title
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years at the time of signing informed consent
- Able to provide written informed consent
- Diagnosed with persistent dyslipidemias defined by specific triglyceride and LDL cholesterol levels according to ASCVD status
- Dyslipidemia refractory to maximal or maximum tolerated lipid-lowering therapies for at least 12 weeks prior to screening
- Female participants must be postmenopausal or surgically sterile
- Male participants and female partners must agree to use effective contraception during the study
You will not qualify if you...
- Diagnosis of familial chylomicronemia syndrome (FCS), with some exceptions
- Evidence of liver disease including elevated liver function tests, high bilirubin, abnormal INR, or liver stiffness
- Abnormal or impaired kidney, heart, blood, or liver function
- Acute coronary syndrome or stroke within 24 weeks prior to Day 1; acute pancreatitis within 12 weeks prior to Day 1
- Use of hepatocyte-targeted small interfering RNA treatments within 365 days prior to Day 1 (except inclisiran)
- Positive tests for HIV, hepatitis B, or hepatitis C (except prior immunization)
- Any malignancy within the past 5 years or current malignancy (except certain skin and cervical/breast cancers)
- Women of childbearing potential
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Research Site 10
Jacksonville, Florida, United States, 32216
Not Yet Recruiting
2
Research Site 17
Orlando, Florida, United States, 32789
Not Yet Recruiting
3
Research Site 11
Port Orange, Florida, United States, 32127
Not Yet Recruiting
4
Research Site 14
Durham, North Carolina, United States, 27710
Not Yet Recruiting
5
Research Site 13
High Point, North Carolina, United States, 27260
Not Yet Recruiting
6
Research Site 9
Cleveland, Ohio, United States, 44195
Not Yet Recruiting
7
Research Site 12
Portland, Oregon, United States, 97239
Not Yet Recruiting
8
Research Site 1
Adelaide, Australia, 5000
Actively Recruiting
9
Research Site 15
Brisbane, Australia, 4064
Not Yet Recruiting
10
Research Site 16
Brisbane, Australia
Not Yet Recruiting
11
Research Site 7
Camperdown, Australia, 2050
Not Yet Recruiting
12
Research Site 3
Heidelberg, Australia, 3084
Actively Recruiting
13
Research Site 2
Melbourne, Australia, 3168
Actively Recruiting
14
Research Site 5
Auckland, New Zealand, 2025
Actively Recruiting
15
Research Site 4
Christchurch, New Zealand, 8011
Actively Recruiting
16
Research Site 18
Cambridge, United Kingdom
Not Yet Recruiting
17
Research Site 8
London, United Kingdom, E1 1BB
Not Yet Recruiting
18
Research Site 6
London, United Kingdom, SE1 1YR
Actively Recruiting
Research Team
C
Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here